Table 3. Frequency of HTRA1 (rs11200638) alleles and genotypes in NVAMD patients and unaffected controls.
| HTRA1 (rs1200638) | AMD | Unaffected | p | OR (95% CI) |
|---|---|---|---|---|
| By allele | ||||
| Entire population (G/A; %) |
325/185
(63.7/36.3) |
197/41
(82.8/17.2) |
<0.0001 |
2.7 (1.9–4) |
| Ashkenazi Jews |
212/114
(65/35) |
114/22
(83.8/16.2) |
<0.0001 |
2.8 (1.7–4.6) |
| Sephardic Jews |
95/55
(63/37) |
65/15
(81.3/18.7) |
0.0065 |
2.5 (1.3–4.8) |
| Arabs |
10/12
(45.4/54.6) |
17/3
(0.85/0.15) |
0.01 |
6.8 (1.5–30.1) |
| By genotype | ||||
| Entire population |
|
|
<0.0001 |
|
| GG (%) |
116 (45.5) |
81 (68.1) |
|
|
| GA (%) |
93 (36.5) |
35 (29.4) |
0.013 |
1.8 (1.1–3.0) |
| AA (%) |
46 (18.0) |
3 (2.5) |
<0.0001 |
10.7 (3.2–35.7) |
| Ashkenazi Jews |
|
|
0.011 |
|
| GG (%) |
80 (49.1) |
48 (70.6) |
|
|
| GA (%) |
52 (31.9) |
18 (26.5) |
0.24 |
1.5 (3–0.76) |
| AA (%) |
31 (19) |
2 (2.9) |
0.009 |
7.2 (31.2–1.6) |
| Sephardic Jews |
|
|
0.02 |
|
| GG (%) |
30 (40) |
26 (65) |
|
|
| GA (%) |
35 (46.7) |
13 (32.5) |
0.044 |
2.3 (5.3–1.02) |
| AA (%) |
10 (13.3) |
1 (2.5) |
0.046 |
8.7 (71.5–1.04) |
| Arabs# |
|
|
0.05 |
|
| GG (%) |
4 (36.4) |
7 (70) |
|
|
| GA (%) |
2 (18.1) |
3 (30) |
|
|
| AA (%) | 5 (45.5) | 0 (0) | ||
Comparison of the frequency (%) of the HTRA1 (rs11200638) variant between NVAMD patients and controls in the entire Israeli population and in the Ashkenazi, Sephardic, and Arab subpopulations. Increased prevalence of the A variant was associated with the disease in the entire population as well as in Ashkenazi, Sephardic, and Arab subpopulation. CI- confidence interval, OR- odds ratio. The hash mark represents there were too few Arabs to obtain reliable ORs and CIs for analysis of genotypes in this sub population.